Biological
Favezelimab clinical trials
Also written MK-4280.
- studies test it
- 13
- open now
- 1
- in phase 3
- 3
- first study started
- 2016
Keep track of what changes. Save the favezelimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 2 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 9
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Often tested with
Tested in the same studies.
Pembrolizumab (13) · Lenvatinib (5) · Pembrolizumab/Quavonlimab MK-1308A (4) · Vibostolimab (3) · Belzutifan (2) · Vibostolimab/Pembrolizumab MK-7684A (1) · Tretinoin (1) · Olaparib (1)
Studies
Open first, then newest update. How each study uses favezelimab is read from its arms, and is right about nine times in ten.
Testing it · 13
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)RecruitingPhase 3Merck Sharp & Dohme LLCNCT03486873Written as MK-4280
- Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT04626518Written as Favezelimab/Pembrolizumab
- Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT04626479Written as Favezelimab/Pembrolizumab
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)CompletedPhase 2Merck Sharp & Dohme LLCNCT05508867Written as favezelimab/pembrolizumab
- Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT04303169Written as Favezelimab + Pembrolizumab
- Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)TerminatedPhase 1/2Merck Sharp & Dohme LLCNCT03598608Written as Favezelimab
- Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT04895722Written as Pembrolizumab/Favezelimab
- Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT04305054Written as Favezelimab/Pembrolizumab
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)CompletedPhase 3Merck Sharp & Dohme LLCNCT05064059Written as favezelimab/pembrolizumab
- Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)CompletedPhase 2Merck Sharp & Dohme LLCNCT06036836Written as favezelimab/pembrolizumab
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension StudyCompletedPhase 3Merck Sharp & Dohme LLCNCT05600309Written as favezelimab/pembrolizumab
- Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)CompletedPhase 1Merck Sharp & Dohme LLCNCT02720068Written as Favezelimab
- A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)WithdrawnPhase 1/2Merck Sharp & Dohme LLCNCT06395090Written as Favezelimab
Given in every arm · 1 — favezelimab is usual care beside what is tested
Codes
What other systems call favezelimab · ClinicalTrials.gg INT016725
- UNII (FDA) H1396W7D1HFAVEZELIMABOne source FDA
- NCI Thesaurus C142077FavezelimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | H1396W7D1H | FAVEZELIMAB | One source FDA |
| NCI Thesaurus | C142077 | Favezelimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.